Denosumab for the Prevention of Fragility Fractures in Hemodialysis: a Pilot Study for an Innovative, Randomized-controlled Trial, Embedded in Routine Care
Latest Information Update: 20 Sep 2024
Price :
$35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Fracture
- Focus Therapeutic Use
- Acronyms PREFERRED-1
- 09 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 13 Jan 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.